Home> Products> steris healthcare diabetes medications

{ "products": [ { "_id": "66d83ad4ed345980e0fca5c5", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Voglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)", "description": "GLICLAGLAZE TRIO 0.3 \nVoglibose (0.3mg), Metformin (500mg), Gliclazide (80mg)\nGLICLAGLAZE TRIO 0.3 is a powerful combination medication designed to manage and control type 2 diabetes. It is formulated with three active ingredients: Voglibose, Metformin, and Gliclazide. This unique combination helps to regulate blood sugar levels effectively, providing a comprehensive approach to diabetes management. GLICLAGLAZE TRIO 0.3 is particularly useful for patients who require a multifaceted treatment strategy to keep their blood glucose levels in check.\n\n \n\nKey Benefits:\n \n\nEffective Blood Sugar Control: The combination of Voglibose, Metformin, and Gliclazide offers a synergistic effect, providing comprehensive control over blood sugar levels.\nPrevents Post-Meal Sugar Spikes: Voglibose helps in delaying glucose absorption, reducing the risk of hyperglycemia after meals.\nImproved Insulin Sensitivity: Metformin enhances the body's response to insulin, ensuring better glucose management.\nEnhanced Insulin Secretion: Gliclazide helps in stimulating insulin release from the pancreas, making it easier to maintain stable blood sugar levels.\n \n\nHow Does It Work?\n \n\nGLICLAGLAZE TRIO 0.3 works through a multi-pronged approach to manage diabetes. Voglibose slows down the absorption of carbohydrates in the gut, which helps to prevent rapid increases in blood sugar levels after meals. Metformin reduces the liver's glucose production and improves insulin sensitivity, ensuring better glucose uptake and utilization. Gliclazide stimulates the pancreas to release insulin, aiding in the reduction of blood glucose levels.\n\n \n\nDirections for Use:\n \n\nTake GLICLAGLAZE TRIO 0.3 as prescribed by your healthcare provider. It is typically taken before meals to maximize its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a glass of water. Do not crush or chew the tablet. Your doctor will determine the appropriate dosage and frequency based on your individual health needs.\n\n \n\nSide Effects:\n \n\nLike all medications, GLICLAGLAZE TRIO 0.3 may cause some side effects. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Hypoglycemia (low blood sugar) may occur, especially if you skip meals or engage in intense physical activity. Other possible side effects include dizziness, headache, and fatigue. If you experience any severe side effects or allergic reactions, seek medical attention immediately.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 185.0, "discountamount": 56.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Key Benefits", "abdominal pain", "glucose uptake", "type 2 diabetes", "rapid increases", "insulin release", "low blood sugar", "GLICLAGLAZE TRIO", "medical attention", "glucose absorption", "allergic reactions", "appropriate dosage", "synergistic effect", "unique combination", "glucose production", "glucose management", "diabetes management", "healthcare provider", "severe side effects", "Common side effects", "blood glucose levels", "comprehensive control", "multi-pronged approach", "comprehensive approach", "Post-Meal Sugar Spikes", "individual health needs", "three active ingredients", "intense physical activity", "stable blood sugar levels", "Enhanced Insulin Secretion", "Other possible side effects", "Improved Insulin Sensitivity", "gastrointestinal disturbances", "Effective Blood Sugar Control", "powerful combination medication", "multifaceted treatment strategy", "postprandial blood sugar spikes" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1962, "imageuri": "https://productimages.withfloats.com/actual/66d83afac7293b3595ec4ea6.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/66d83afac7293b3595ec4ea6.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-09-04T10:47:48.369Z", "updatedon": "2024-09-04T10:47:48.369Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/voglibose-0-3mg-metformin-500mg-gliclazide-80mg-/1962", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE TRIO 0.3 ", "category": "DIABETIC RANGE", "tags": null, "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668d24ff75f1701d34699e32", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLICLAGLAZE 80 ", "description": "GLICLAGLAZE 80 \nGliclazide (80mg)\nOverview\nGLICLAGLAZE 80 is an oral medication containing Gliclazide at a dosage of 80 mg. Gliclazide belongs to the class of drugs known as sulfonylureas and is primarily used to manage type 2 diabetes mellitus. It helps control blood sugar levels by stimulating the release of insulin from the pancreatic beta cells. GLICLAGLAZE 80 is an effective treatment option for individuals who require oral hypoglycemic therapy to maintain optimal blood glucose levels.\n\nBenefits of Gliclazide\n\nBlood Sugar Control\n\nGliclazide effectively lowers blood glucose levels by increasing insulin secretion.\nHelps prevent complications associated with diabetes, such as neuropathy, nephropathy, and retinopathy.\nReduced Risk of Hypoglycemia\n\nCompared to some other sulfonylureas, Gliclazide has a lower risk of causing hypoglycemia (low blood sugar levels).\nIt provides a balanced approach to managing blood sugar without causing excessive drops in glucose levels.\nCardiovascular Benefits\n\nStudies suggest that Gliclazide may have a protective effect on the cardiovascular system.\nIt may reduce the risk of cardiovascular events in diabetic patients, promoting overall heart health.\nImproved Glycemic Control\n\nHelps achieve and maintain target HbA1c levels, reflecting long-term glycemic control.\nCan be used in combination with other oral antidiabetic agents or insulin to enhance its effectiveness.\nUsage and Dosage\nGLICLAGLAZE 80 should be taken as prescribed by a healthcare professional. The typical starting dose is 40 to 80 mg daily, which can be adjusted based on the patient's blood glucose response. It is usually taken with meals to maximize its effectiveness and minimize gastrointestinal side effects. Consistent use and adherence to prescribed dosage are crucial for optimal results.\n\nIndications for Use\n\nType 2 Diabetes Mellitus: GLICLAGLAZE 80 is indicated for the management of type 2 diabetes in patients who cannot achieve adequate glycemic control through diet and exercise alone.\nCombination Therapy: It can be used in conjunction with other oral hypoglycemic agents or insulin to achieve better blood sugar control.\nSide Effects\nGLICLAGLAZE 80 is generally well-tolerated. However, some patients may experience side effects, including:\n\nHypoglycemia: Although less common, low blood sugar can occur, especially if meals are skipped or combined with excessive physical activity.\nGastrointestinal Issues: Nausea, abdominal pain, and diarrhea may occur but are usually mild and transient.\nAllergic Reactions: Rarely, allergic reactions such as skin rash, itching, or hives may occur.\nPrecautions and Contraindications\n\nLiver and Kidney Impairment: Patients with severe liver or kidney disease should use GLICLAGLAZE 80 with caution, as it may require dose adjustments.\nPregnancy and Lactation: Gliclazide is not recommended during pregnancy or breastfeeding. Alternative treatments should be considered.\nDrug Interactions: Inform your healthcare provider about all medications and supplements you are taking, as Gliclazide can interact with other drugs, potentially altering its effectiveness.\nConclusion\nGLICLAGLAZE 80 is a reliable and effective oral medication for managing type 2 diabetes mellitus. By stimulating insulin secretion, it helps control blood sugar levels, reducing the risk of diabetes-related complications. Its balanced approach to glycemic control, combined with potential cardiovascular benefits, makes GLICLAGLAZE 80 a valuable addition to diabetes management plans. Under the guidance of a healthcare professional, GLICLAGLAZE 80 can significantly improve the quality of life for individuals with type 2 diabetes, promoting better long-term health outcomes.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 265.0, "discountamount": 79.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "skin rash", "lower risk", "40 to 80 mg", "other drugs", "severe liver", "Reduced Risk", "Consistent use", "kidney disease", "abdominal pain", "excessive drops", "optimal results", "dose adjustments", "diabetic patients", "insulin secretion", "valuable addition", "Drug Interactions", "Kidney Impairment", "protective effect", "balanced approach", "Allergic Reactions", "healthcare provider", "Combination Therapy", "other sulfonylureas", "Blood Sugar Control", "target HbA1c levels", "overall heart health", "cardiovascular events", "cardiovascular system", "typical starting dose", "pancreatic beta cells", "Alternative treatments", "blood glucose response", "low blood sugar levels", "healthcare professional", "Gastrointestinal Issues", "type 2 diabetes mellitus", "diabetes management plans", "adequate glycemic control", "effective oral medication", "long-term health outcomes", "oral hypoglycemic therapy", "long-term glycemic control", "effective treatment option", "excessive physical activity", "optimal blood glucose levels", "gastrointestinal side effects", "diabetes-related complications", "other oral hypoglycemic agents", "other oral antidiabetic agents", "potential cardiovascular benefits" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1922, "imageuri": "https://productimages.withfloats.com/actual/668d2505c34ba6457aa3fb4d.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668d2505c34ba6457aa3fb4d.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-09T11:54:39.186Z", "updatedon": "2024-07-09T11:54:39.186Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/gliclaglaze-80-/1922", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLICLAGLAZE 80 ", "category": "DIABETIC RANGE", "tags": [ "Gliclazide 80mg side effects", "Gliclazide 80mg dosage", "Gliclazide 80mg Metformin 500mg", "Gliclazide 80mg price", "Gliclazide 80mg uses", "Gliclazide 80mg Uses in Hindi", "Gliclazide 80mg before or after meal" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668d1f7b6be1220f389cf9a3", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "THYRORISE 200 ", "description": "THYRORISE 200 \nThyroxine Sodium (200mcg)\nOverview\nTHYRORISE 200 is a pharmaceutical formulation containing Thyroxine Sodium, a synthetic form of the thyroid hormone thyroxine (T4), at a dosage of 200 mcg. Thyroxine is crucial for regulating metabolism, energy production, and overall endocrine health. THYRORISE 200 is prescribed for individuals with hypothyroidism, a condition where the thyroid gland does not produce enough hormones, leading to symptoms such as fatigue, weight gain, and depression.\n\nBenefits of Thyroxine Sodium\n\nRegulation of Metabolism\n\nThyroxine plays a vital role in regulating the body's metabolic rate.\nIt helps convert food into energy, supporting weight management and energy levels.\nSupport for Cardiovascular Health\n\nProper levels of thyroxine ensure the normal function of the heart.\nIt helps maintain healthy heart rate and blood pressure, reducing the risk of cardiovascular diseases.\nEnhancement of Cognitive Function\n\nAdequate thyroxine levels are essential for brain development and function.\nIt improves cognitive abilities, memory, and concentration, preventing cognitive decline.\nMood Stabilization\n\nThyroxine helps regulate mood and emotional well-being.\nIt can alleviate symptoms of depression and anxiety associated with hypothyroidism.\nHealthy Growth and Development\n\nCrucial for normal growth and development in children.\nEnsures proper development of bones, muscles, and the nervous system.\nUsage and Dosage\nTHYRORISE 200 should be taken as prescribed by a healthcare professional. The typical starting dose for adults with hypothyroidism is individualized based on the patient's age, weight, cardiovascular status, and other health conditions. It is usually taken once daily on an empty stomach, preferably 30 minutes to an hour before breakfast to enhance absorption.\n\nIndications for Use\n\nHypothyroidism: Effective in treating primary, secondary, and tertiary hypothyroidism.\nGoiter: Helps reduce the size of an enlarged thyroid gland.\nThyroid Cancer: Used as part of the treatment regimen for certain types of thyroid cancer.\nThyroid Hormone Replacement: For patients with thyroidectomy or radioactive iodine therapy.\nSide Effects\nWhile THYRORISE 200 is generally well-tolerated, some individuals may experience side effects, especially if the dosage is not properly adjusted. Possible side effects include:\n\nCardiovascular Issues: Palpitations, increased heart rate, and hypertension.\nNervous System Effects: Nervousness, irritability, and tremors.\nGastrointestinal Symptoms: Diarrhea, weight loss, and increased appetite.\nOthers: Hair loss, muscle weakness, and menstrual irregularities.\nPrecautions and Contraindications\n\nCardiovascular Conditions: Patients with heart disease or hypertension should use THYRORISE 200 with caution and under close medical supervision.\nDiabetes: Thyroxine can affect blood sugar levels; diabetic patients may need adjustments to their diabetes medication.\nPregnancy and Lactation: Adequate thyroxine levels are crucial during pregnancy; however, dosage adjustments may be necessary. Consult a healthcare provider.\nDrug Interactions: Thyroxine can interact with various medications, including anticoagulants, insulin, and certain antidepressants. Inform your healthcare provider of all medications you are taking.\nConclusion\nTHYRORISE 200 provides an effective solution for individuals with hypothyroidism and related conditions. By supplementing the body's thyroxine levels, it helps restore normal metabolic function, enhances cardiovascular and cognitive health, and improves overall well-being. Under the guidance of a healthcare professional, THYRORISE 200 can significantly improve the quality of life for those suffering from thyroid hormone deficiencies.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 260.0, "discountamount": 78.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Hair loss", "vital role", "weight loss", "weight gain", "heart disease", "empty stomach", "energy levels", "normal growth", "Proper levels", "synthetic form", "Thyroid Cancer", "Healthy Growth", "blood pressure", "metabolic rate", "muscle weakness", "enough hormones", "normal function", "Thyroxine Sodium", "cognitive health", "diabetic patients", "brain development", "energy production", "weight management", "Drug Interactions", "treatment regimen", "cognitive decline", "dosage adjustments", "proper development", "Mood Stabilization", "effective solution", "Cognitive Function", "related conditions", "overall well-being", "healthy heart rate", "blood sugar levels", "various medications", "diabetes medication", "healthcare provider", "cognitive abilities", "emotional well-being", "Cardiovascular Issues", "cardiovascular status", "Cardiovascular Health", "Possible side effects", "typical starting dose", "Nervous System Effects", "enlarged thyroid gland", "tertiary hypothyroidism", "cardiovascular diseases", "healthcare professional", "other health conditions", "menstrual irregularities", "overall endocrine health", "Gastrointestinal Symptoms", "Cardiovascular Conditions", "normal metabolic function", "Adequate thyroxine levels", "close medical supervision", "pharmaceutical formulation", "radioactive iodine therapy", "Thyroid Hormone Replacement", "thyroid hormone deficiencies" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1920, "imageuri": "https://productimages.withfloats.com/actual/668d1fa94944b8c562115315.png", "tileimageuri": "https://productimages.withfloats.com/tile/668d1fa94944b8c562115315.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-09T11:31:07.271Z", "updatedon": "2024-07-09T11:31:07.271Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/thyrorise-200-/1920", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "THYRORISE 200 ", "category": "DIABETICSRANGE", "tags": [ "Thyroxine 200 mg side effects", "is 200 mcg of levothyroxine, a high dose", "Thyroxine 200 mg uses", "Thyrox 200 mg", "Thyronorm 200 mcg uses", "Thyroxine Sodium Tablets" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662cd3e870e7b20c49e689e", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD G3 M0.3 ", "description": "VOGLIGOLD G3 M0.3 \nVoglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg\nIntroduction to VOGLIGOLD G3 M0.3\nVOGLIGOLD G3 M0.3 is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains three active ingredients: Voglibose 0.3mg, Glimepiride 3mg, and Metformin Hydrochloride 500mg. This multi-action formula targets different aspects of glucose regulation to provide comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVoglibose 0.3mg\nVoglibose is an alpha-glucosidase inhibitor that works by:\n\nSlowing Carbohydrate Absorption: Voglibose inhibits the alpha-glucosidase enzyme in the small intestine, delaying the breakdown of complex carbohydrates into glucose. This helps to smooth out postprandial (after-meal) blood glucose peaks.\nGlimepiride 3mg\nGlimepiride is a sulfonylurea that helps control blood sugar by:\n\nStimulating Insulin Secretion: Glimepiride stimulates the pancreas to release more insulin, which helps lower blood sugar levels, particularly after meals.\nMetformin Hydrochloride 500mg\nMetformin is a biguanide that helps lower blood sugar levels through several mechanisms:\n\nReducing Hepatic Glucose Production: Metformin decreases the amount of glucose produced by the liver.\nImproving Insulin Sensitivity: It enhances the sensitivity of muscle cells to insulin, promoting better glucose uptake and utilization.\nDecreasing Intestinal Absorption of Glucose: Metformin reduces the absorption of glucose from the gastrointestinal tract.\nBenefits of VOGLIGOLD G3 M0.3\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Voglibose, Glimepiride, and Metformin effectively manages both fasting and postprandial blood sugar levels.\nEnhanced Insulin Secretion and Sensitivity: Glimepiride enhances insulin secretion, while Metformin improves insulin sensitivity, and Voglibose slows carbohydrate absorption.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: The risk of hypoglycemia is minimized due to the complementary actions of the three components.\nWeight Neutrality: Metformin and Voglibose are generally weight neutral, making this combination favorable for patients concerned about weight gain associated with diabetes medications.\nHow to Use VOGLIGOLD G3 M0.3\nDosage and Administration\nRecommended Dosage: The typical dosage is one tablet taken once or twice daily, as prescribed by your healthcare provider.\nAdministration: Take the tablet with meals to reduce gastrointestinal side effects and enhance the absorption of Metformin. Swallow the tablet whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD G3 M0.3 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-g3-m0-3-134319", "price": 185.0, "discountamount": 55.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "meal", "diet", "Order", "glass", "water", "EMAIL", "liver", "adults", "amount", "Fasting", "readings", "patients", "pancreas", "Low Risk", "exercise", "breakdown", "same time", "biguanide", "Decreasing", "one tablet", "Guidelines", "Glimepiride", "Adjustments", "weight gain", "information", "utilization", "Optimal Use", "best results", "Introduction", "sterispharma", "sulfonylurea", "Hypoglycemia", "muscle cells", "sterisonline", "CALL/WHATSAPP", "Voglibose 0.3", "Administration", "typical dosage", "glucose uptake", "treatment plan", "Consistent Use", "Key Components", "small intestine", "glycemic control", "three components", "VOGLIGOLD G3 M0.3", "different aspects", "Weight Neutrality", "several mechanisms", "glucose regulation", "Regular monitoring", "Recommended Dosage", "blood glucose peaks", "Insulin Sensitivity", "healthcare provider", "diabetes medications", "effective management", "multi-action formula", "complex carbohydrates", "Intestinal Absorption", "complementary actions", "gastrointestinal tract", "combination medication", "Metformin Hydrochloride", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "three active ingredients", "type 2 diabetes mellitus", "Enhanced Insulin Secretion", "Additional Health Benefits", "Hepatic Glucose Production", "alpha-glucosidase inhibitor", "gastrointestinal side effects", "Postprandial Glucose Management", "postprandial blood sugar levels", "comprehensive blood sugar control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1519, "imageuri": "https://productimages.withfloats.com/actual/667d30b6c303c6d6ad136ea4.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d30b6c303c6d6ad136ea4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T09:05:02.904Z", "updatedon": "2024-06-27T09:28:16.215Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vogligold-g3-m0-3-/1519", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD G3 M0.3 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 3mg+metformin 500mg+voglibose 0.3 mg", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662cb8e161afa2274ff6309", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.3 ", "description": "VOGLIGOLD 0.3 \nVoglibose (0.3mg)\nIntroduction to VOGLIGOLD 0.3\nVOGLIGOLD 0.3 is an oral medication designed to help manage type 2 diabetes mellitus by controlling blood sugar levels. It contains Voglibose, an alpha-glucosidase inhibitor that works by slowing the digestion and absorption of carbohydrates in the intestines. This mechanism helps prevent spikes in blood sugar levels after meals. VOGLIGOLD 0.3 is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVoglibose 0.3mg\nVoglibose is a potent alpha-glucosidase inhibitor. It functions by inhibiting the alpha-glucosidase enzyme in the small intestine, which is responsible for breaking down complex carbohydrates into simple sugars. By inhibiting this enzyme, Voglibose slows down the conversion of carbohydrates into glucose, thereby reducing the postprandial (after-meal) rise in blood sugar levels.\n\nSlows Carbohydrate Absorption: By delaying the absorption of glucose, Voglibose helps to smooth out the postprandial blood glucose peaks.\nReduces Postprandial Hyperglycemia: It specifically targets the blood sugar spikes that occur after meals, making it an effective treatment for controlling postprandial hyperglycemia.\nBenefits of VOGLIGOLD 0.3\nEffective Postprandial Blood Sugar Control\nManages After-Meal Blood Sugar Levels: VOGLIGOLD 0.3 helps to manage and reduce the rise in blood sugar levels that occur after meals.\nComplementary Therapy: It can be used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to provide comprehensive glycemic control.\nAdditional Health Benefits\nWeight Neutral: Voglibose is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Voglibose has a low risk of causing hypoglycemia (low blood sugar), as it does not increase insulin secretion directly.\nHow to Use VOGLIGOLD 0.3\nDosage and Administration\nRecommended Dosage: The typical dosage of VOGLIGOLD 0.3 is one tablet taken three times a day, just before meals.\nAdministration: Take the tablet whole with a glass of water, just before starting your meal. This timing ensures that the medication works effectively by inhibiting the enzyme responsible for carbohydrate digestion.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD 0.3 regularly at the same times each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/st-gliptin-dapa-100-10-134075", "price": 119.0, "discountamount": 35.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "dapa", "rise", "diet", "Order", "water", "EMAIL", "meals", "glass", "option", "timing", "Action", "adults", "gliptin", "patients", "exercise", "readings", "Low Risk", "metformin", "VOGLIGOLD", "Voglibose", "mechanism", "Guidelines", "conversion", "same times", "intestines", "one tablet", "Optimal Use", "weight gain", "combination", "information", "Adjustments", "Introduction", "Hypoglycemia", "sterisonline", "best results", "sterispharma", "sulfonylureas", "CALL/WHATSAPP", "simple sugars", "Key Component", "treatment plan", "typical dosage", "Administration", "Consistent Use", "Weight Neutral", "low blood sugar", "small intestine", "oral medication", "insulin secretion", "Regular monitoring", "Recommended Dosage", "blood sugar spikes", "effective treatment", "healthcare provider", "complex carbohydrates", "Complementary Therapy", "carbohydrate digestion", "Meal Blood Sugar Levels", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "type 2 diabetes mellitus", "Postprandial Hyperglycemia", "Additional Health Benefits", "other diabetes medications", "comprehensive glycemic control", "other antidiabetic medications", "postprandial blood glucose peaks", "potent alpha-glucosidase inhibitor", "Effective Postprandial Blood Sugar Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1518, "imageuri": "https://productimages.withfloats.com/actual/667d3145422dd0be26724c0b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3145422dd0be26724c0b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:57:50.904Z", "updatedon": "2024-06-27T09:30:42.497Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vogligold-0-3-/1518", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD 0.3 ", "category": "DIABETIC RANGE", "tags": [ "voglibose 0.3mg price", "voglibose 0.3mg dosage", "voglibose 0.3mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c935a743fd2358222332", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VOGLIGOLD 0.2 ", "description": "VOGLIGOLD 0.2 \nVoglibose (0.2mg)\nIntroduction to VOGLIGOLD 0.2\nVOGLIGOLD 0.2 is a medication designed to manage type 2 diabetes mellitus by helping to control blood sugar levels. It contains Voglibose, an alpha-glucosidase inhibitor, which works by slowing down the digestion and absorption of carbohydrates from the intestines. This action helps to prevent spikes in blood sugar levels after meals. VOGLIGOLD 0.2 is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVoglibose 0.2mg\nVoglibose is a potent alpha-glucosidase inhibitor. It works by inhibiting the alpha-glucosidase enzyme in the small intestine, which is responsible for breaking down complex carbohydrates into simple sugars. By inhibiting this enzyme, Voglibose slows down the conversion of carbohydrates into glucose, thereby reducing the postprandial (after-meal) rise in blood sugar levels.\n\nSlows Carbohydrate Absorption: By delaying the absorption of glucose, Voglibose helps to smooth out the postprandial blood glucose peaks.\nReduces Postprandial Hyperglycemia: It specifically targets the blood sugar spikes that occur after meals, making it an effective treatment for controlling postprandial hyperglycemia.\nBenefits of VOGLIGOLD 0.2\nEffective Postprandial Blood Sugar Control\nManages After-Meal Blood Sugar Levels: VOGLIGOLD 0.2 helps to manage and reduce the rise in blood sugar levels that occur after meals.\nComplementary Therapy: It can be used in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin to provide comprehensive glycemic control.\nAdditional Health Benefits\nWeight Neutral: Voglibose is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nLow Risk of Hypoglycemia: When used alone, Voglibose has a low risk of causing hypoglycemia (low blood sugar), as it does not increase insulin secretion directly.\nHow to Use VOGLIGOLD 0.2\nDosage and Administration\nRecommended Dosage: The typical dosage of VOGLIGOLD 0.2 is one tablet taken three times a day, just before meals.\nAdministration: Take the tablet whole with a glass of water, just before starting your meal. This timing ensures that the medication works effectively by inhibiting the enzyme responsible for carbohydrate digestion.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VOGLIGOLD 0.2 regularly at the same times each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vogligold-0-2-133456", "price": 89.0, "discountamount": 26.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "rise", "diet", "Order", "EMAIL", "meals", "glass", "water", "option", "action", "adults", "timing", "patients", "Low Risk", "exercise", "readings", "metformin", "VOGLIGOLD", "Voglibose", "Mechanism", "Guidelines", "intestines", "same times", "one tablet", "conversion", "Optimal Use", "weight gain", "conjunction", "Adjustments", "combination", "information", "Introduction", "Hypoglycemia", "sterisonline", "sterispharma", "best results", "simple sugars", "CALL/WHATSAPP", "Key Component", "sulfonylureas", "Weight Neutral", "typical dosage", "treatment plan", "Administration", "Consistent Use", "small intestine", "low blood sugar", "insulin secretion", "blood sugar spikes", "Recommended Dosage", "Regular monitoring", "healthcare provider", "effective treatment", "complex carbohydrates", "Complementary Therapy", "carbohydrate digestion", "Meal Blood Sugar Levels", "Carbohydrate Absorption", "alpha-glucosidase enzyme", "type 2 diabetes mellitus", "Postprandial Hyperglycemia", "Additional Health Benefits", "other diabetes medications", "comprehensive glycemic control", "other antidiabetic medications", "postprandial blood glucose peaks", "potent alpha-glucosidase inhibitor", "Effective Postprandial Blood Sugar Control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1515, "imageuri": "https://productimages.withfloats.com/actual/667d34025e58b0758f70570b.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d34025e58b0758f70570b.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:47:49.18Z", "updatedon": "2024-06-27T09:42:22.871Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vogligold-0-2-/1515", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VOGLIGOLD 0.2 ", "category": "DIABETIC RANGE", "tags": [ "voglibose side effects", "voglibose 0.2 mg side effects", "voglibose 0.2mg dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c81c7247ae19c482b3d9", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE 100 ", "description": "VILDIABATE 100 \nVildagliptin (100mg)\nIntroduction to VILDIABATE 100\nVILDIABATE 100 is an oral medication designed for the management of type 2 diabetes mellitus. It contains Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Vildagliptin helps regulate blood sugar levels by enhancing the body’s natural ability to produce insulin and control glucose production. This medication is used in conjunction with diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Component and Mechanism of Action\nVildagliptin 100mg\nVildagliptin is a potent and selective DPP-4 inhibitor. It works by inhibiting the DPP-4 enzyme, which is responsible for breaking down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These incretin hormones play a crucial role in glucose metabolism:\n\nGLP-1: Stimulates insulin secretion from the pancreatic beta cells in a glucose-dependent manner, inhibits glucagon release, slows gastric emptying, and reduces appetite.\nGIP: Enhances insulin secretion post-meal, aiding in the regulation of blood glucose levels.\nBy increasing the levels of these incretin hormones, Vildagliptin helps to improve insulin secretion in response to meals and reduces the amount of glucose produced by the liver.\n\nBenefits of VILDIABATE 100\nEffective Blood Sugar Control\nPostprandial Glucose Control: VILDIABATE 100 helps manage postprandial (after-meal) blood sugar levels by enhancing the body's natural response to food intake.\nFasting Glucose Control: By reducing hepatic glucose production, it also helps lower fasting blood sugar levels.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nWeight Neutral: Vildagliptin is generally weight neutral, making it a favorable option for patients concerned about weight gain associated with other diabetes medications.\nHow to Use VILDIABATE 100\nDosage and Administration\nRecommended Dosage: The typical dosage of VILDIABATE 100 is one tablet taken once or twice daily, depending on individual needs and the healthcare provider's instructions.\nAdministration: Take the tablet with or without food. Swallow it whole with a glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE 100 regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is important to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-100-133452", "price": 275.0, "discountamount": 82.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "body", "EMAIL", "Order", "meals", "water", "glass", "GLP-1", "liver", "adults", "Action", "amount", "option", "potent", "readings", "Low Risk", "appetite", "exercise", "patients", "same time", "Mechanism", "regulation", "VILDIABATE", "one tablet", "Guidelines", "management", "food intake", "weight gain", "Optimal Use", "information", "conjunction", "Adjustments", "Introduction", "Vildagliptin", "sterisonline", "best results", "crucial role", "DPP-4 enzyme", "Hypoglycemia", "instructions", "sterispharma", "Key Component", "CALL/WHATSAPP", "typical dosage", "Consistent Use", "Administration", "treatment plan", "Weight Neutral", "natural ability", "oral medication", "low blood sugar", "glucagon release", "DPP-4) inhibitor", "natural response", "glycemic control", "individual needs", "gastric emptying", "insulin secretion", "incretin hormones", "glucose metabolism", "Recommended Dosage", "Regular monitoring", "healthcare provider", "blood glucose levels", "pancreatic beta cells", "dipeptidyl peptidase-4", "Fasting Glucose Control", "meal) blood sugar levels", "type 2 diabetes mellitus", "glucose-dependent manner", "selective DPP-4 inhibitor", "Additional Health Benefits", "hepatic glucose production", "other diabetes medications", "Postprandial Glucose Control", "Effective Blood Sugar Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1514, "imageuri": "https://productimages.withfloats.com/actual/667d3bc9c134db5b38ba8354.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3bc9c134db5b38ba8354.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:43:08.09Z", "updatedon": "2024-06-27T10:15:31.785Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/vildiabate-100-/1514", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE 100 ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin 100 mg uses", "", "vildagliptin 100 mg generic medicine", "vildagliptin 100 mg side effects", "", "vildagliptin sustained release tablets 100 mg", "vildagliptin 100 mg brands in india" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }